Recent advances in GRDDS


Published on

Published in: Education
1 Comment
  • nice work sir.. please send it at
    Are you sure you want to  Yes  No
    Your message goes here
No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Recent advances in GRDDS

  1. 1. L. J Institute of Pharmacy (M.Pharm Sem-II-2012-13)GRDDS Department of Pharmaceutical Technology Prepared by: Harshil SenjaliaGuided by:Dr. Shreeraj Shah Pushpraj RanaAssociate Professor Sahil Shaikh Vikas Kurmi
  2. 2.  Introduction to GRDDS. GRDDS approaches and classification. Publications covering recent advances/Innovations in GRDDS. Review of recent Patents related to GRDDS. References. 2/32
  3. 3.  Gastro-retentive drug delivery system (GRDDS) is one of the site specific delivery of the drugs at stomach. It is obtained by retaining dosage form into stomach and drug is being released at sustained manner to specific site either in stomach or intestine. 3/32
  4. 4. 4/32
  5. 5. Here, the drug is incorporated withbio/Muco-adhesive agents, enablingthe device to adhere to the stomachwalls, Thus resisting gastric emptying.However, the mucus on the walls ofthe Stomach is in a state of constantrenewal, Resulting in unpredictableadherence. 5/32
  6. 6.  The mechanism involved in this system includes the formation of a viscous cohesive gel in contact withRaft gastric fluids, wherein each portion of the liquid swells, forming a continuous layer called a raft. This raft floats on gastric fluids because of low bulk density created by the formation of CO2. 6/32
  7. 7.  Retained in stomach  Useful for poorly water soluble OR  unstable in intestinal Fluid Bulk density : Less than gastric fluid (<1 g/cm3),  so remain buoyant in the stomach  without affecting gastric emptying rate  for prolonged period of time  So drug release slowly at the desired  rate from system 7/32
  8. 8. Also called ‘ PLUG SYSTEM’ •A dosage form in the stomach will withstand gastric transit if it is bigger than the pyloric sphincter •However, the dosage form must be small enough to be swallowed, and 13mm diameter must not cause gastric obstructionExpansion by swelling orunfolding to a large size. either singly or by accumulation. 8/32
  9. 9. Density should be more thenstomach content i.e. 3 gm/cm3Capable to withstand withperistaltic movement ofstomachPrepared by coating or mixingdrug with heavy inert material 9/32
  10. 10. •Caldwell and co-workers proposed the different geometric forms(tetrahedron, ring or planar membrane [4-lobed, disc or 4-limbed crossform]) of bioerodible polymer compressed within a capsule. 10/32
  11. 11. A B(A)Superporous hydrogel in its dry (a) and water-swollen (b) state.(B) Schematic illustrationof the transit of superporous hydrogel.Although these are swellable systems, they differ sufficiently from the conventional types towarrant separate classification. With pore size ranging between 10 nm and 10 µm, absorptionof water by conventional hydrogel is a very slow process and several hours may be needed toreach an equilibrium state during which premature evacuation of the dosage form may occur. 11/32
  12. 12. Journal: International Journal of Pharmaceutics (Volume 255, Issues 1–2, 14 April 2003, Pages 13–32)Authors: Jaspreet Kaur Vasir, Kaustubh Tambwekar, Sanjay Garg,Abstract:The phenomenon of bioadhesion, introduced by Park and Robinson [Park, K., Robinson, J.R., 1984. Bioadhesivepolymers as platforms for oral controlled drug delivery: method to study bioadhesion. Int. J. Pharm. 198, 107–127],has been studied extensively in the last decade and applied to improve the performance of these drug deliverysystems. Recent advances in polymer science and drug carrier technologies have promulgated the development ofnovel drug carriers such as bioadhesive microspheres that have boosted the use of “bioadhesion” in drug delivery.This article presents the spectrum of potential applications of bioadhesive microspheres in controlled drug deliveryranging from the small molecules, to peptides, and to the macromolecular drugs such as proteins,oligonucleotides and even DNA. The development of mucus or cell-specific bioadhesive polymers and theconcepts of cytoadhesion and bioinvasion provide unprecedented opportunities for targeting drugs to specificcells or intracellular compartments. Developments in the techniques for in vitro and in vivo evaluation ofbioadhesive microspheres have also been discussed. 12/32
  13. 13. Journal : International Society for the Study of Xenobiotics (2001, Vol. 33, No. 2 , Pages 149-160)Inventors: Kumaresh S. Soppimath, Anandrao R. Kulkarni, Walter E. Rudzinski and Tejraj M.AminabhaviAbstract:The floating or hydrodynamically controlled drug-delivery systems are useful in gastro retentiveapplications. The present review addresses briefly the physiology of the gastric emptying processwith respect to floating drug-delivery systems. In recent years, the multiparticulate drug-deliverysystems are used in the oral delivery of drugs. One of the approaches toward this goal is to developthe floating microspheres so as to increase the gastric retention time. Such systems have moreadvantages over the single-unit dosage forms. The development of floating microspheres involvesdifferent solvent evaporation techniques to create the hollow inner core. The present reviewaddresses the preparation and characterization of the floating microspheres for the peroral route ofadministration of the drug. 13/32
  14. 14. Journal: Research in Pharmacy 1(4) :10-16, 2011Authors: SuparnaDugal* and Andrea FernandesAbstract:The limited solubility, and therefore bioavailability, of the antimycotic drug, itraconazole, used for thetreatment of intestinal Candidiasis in immunocompromised individuals, has been well documented.Therapeutic regimen in these patients may include daily administration of multiple doses of various drugs.Hence, improving the residence time of therapeutic agents, would ensure a high continuous concentrationin the body and help decrease the dosing frequency. In our current study, we have investigated a novelmethod of drug delivery, developed by utilizing the concept of mucoadhesiveness, for the sustained releaseof the drug, itraconazole. Mucoadhesive beads were prepared using two natural polymers, isabghula huskand alginate. The minimum inhibitory concentration of itraconazole for Candida was found to be1.5milligram per millilitre. Accordingly, beads were prepared by ionic gelation method using calciumchloride as a crosslinking agent. Marked improvement in solubility of the drug was noted after entrapment. 14/32
  15. 15. Journal: DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (Vol. 30, No. 4, pp. 405–412, 2004)Authors: R. Talukder and R. FassihiAbstract:The objective of this study was to develop a floatable multiparticulate system with potential for intragastricsustained drug delivery. Cross-linked beads were made by using calcium and low methoxylated pectin (LMP),which is an anionic polysaccharide, and calcium, LMP, and sodium alginate. Beads were dried separately in an airconvection type oven at 40C for 6 hours and in a freeze dryer to evaluate the changes in bead characteristics dueto process variability. Riboflavin (B-2), tetracycline (TCN), and Methotrexate (MTX) were used as model drugs forencapsulation. Ionic and nonionic excipients were added to study their effects on the release profiles of the beads.The presence of noncross linking agents in low amounts (less than 2%) did not significantly interfere with releasekinetics.y. Evaluation of the drying process demonstrated that the freeze-dried beads remained buoyant over 12hours in United States Pharmacopeia (USP) hydrochloride buffer at pH 1.5, whereas the air-dried beads remainedsubmerged throughout the release study. Confocal laser microscopy revealed the presence of air-filled hollowspaces inside the freeze dried beads, which was responsible for the flotation property of the beads. 15/32
  16. 16. Journal: Indian Journal of Pharmaceutical Education and ResearchAuthors: Ashwani Goyal , Sandeep Kumar , Manju Nagpal , Inderbir Singh and Sandeep AroraAbstract: Recently the use of herbal medicines has been increased all over the world due to theirmiraculous therapeutic effects and fewer adverse effects as compared to the modern medicines. However,delivery of herbal drugs also requires modifications with the purpose to achieve sustained release, toincrease patient compliance etc. Previously herbal drugs could not attract scientists towards thedevelopment of novel drug delivery systems due to processing, standardising, extracting and identificationdifficulties. But now days with the advancement in the technology, novel drug delivery systems opens thedoor towards the development of herbal drug delivery systems. Novel drug delivery technologies havegained the importance to achieve modified delivery of herbal drugs thereby increasing the therapeuticvalue as well as reducing toxicity. For last one decade many novel carriers such as liposomes, nanoparticles,phytosomes and implants have been reported for successful modified delivery of various herbal drugs e.g.curcumin, quercetin, silybin, ginkgo etc. 16/32
  17. 17.  Black Myrobalan(Terminalia Chebula Retz) Ginger Root(Zingiber Officinale Rosc) Turmeric(Curcuma Longa L) Thyme Licorice Berberine Goshuyn(Evodia Rutaecarpa) Other Chinese Herbs: Coptis Chinensis, Rheum Palmatum, Panax Notogenseng, Magnolia Officinalis, Prunus Mume, Corydalis Yanhusuo 17/32
  18. 18. Journal: Pharmacognosy Research(Year : 2010 | Volume : 2 | Issue : 5 | Page : 304-308)Authors: HN Aswatha Ram, Prachiti Lachake, Ujjwal Kaushik, CS ShreedharaAbstract: Floating tablets prolong the gastric residence time of drugs, improve bioavailability, andfacilitate local drug delivery to the stomach. With this objective, floating tablets containing aqueousextract of liquorice as drug was prepared for the treatment of Helicobacter pylori and gastric ulcers.Method: The aqueous extract of liquorice was standardized by HPTLC. Tablets containing HPMCK100M (hydrophilic polymer), liquorice extract, sodium bicarbonate (gas generating agent), talc, andmagnesium stearate were prepared using direct compression method. The formulations wereevaluated for physical parameters like diameter, thickness, hardness, friability, uniformity of weight,drug content, buoyancy time, dissolution, and drug release mechanism. The formulations wereoptimized on the basis of buoyancy time and in vitro drug release. 18/32
  19. 19. Journal: Asian Journal of Pharmaceutical and Clinical Research (Vol 5, Issue 1, 2012 )Authors: CHAKRABORTY M, GUPTA BIJAN KUMAR , DEBNATH R, PAL R.N, KUMAR RAJIBABSTRACT: In the present study, Forskolin, a natural root extract from the Coleus Forskohlii,was developed into a gastro retentive floating drug delivery system, using different grades ofHPMC. The drug is used as anti-obesity agent reducing fat in body muscles. Forskolin increasescAMP accumulation, and therefore stimulates lipolysis. So, with high concentrations offorskolin, cAMP and lipolysis increases Enhanced lipolysis increases fat degradation and fatusage as a fuel in the body. This may promote fat and weight loss. It is thought thatsupplementing with forskolin may enhance fat loss without loss of muscle mass .Presently thedrug is available in conventional capsule dosage form with effect on systolic blood pressure. Infloating drug delivery ,the release rate of drug was controlled minimizing dose related sideeffects. The cumulative drug release was fitted in different kinetic models and statisticallyvalidated. 19/32
  20. 20. Journal: Tropical Journal of Pharmaceutical Research October 2012; 11 (5): 713-719Authors: Kapil Kumar and AK RaiAbstract: Floating microsphere were prepared by emulsion solvent diffusion method,using hydroxylpropyl methylcellulose (HPMC), ethyl cellulose (EC), Eudragit S 100polymer in varying ratios. Ethanol/dichloromethane blend was used as solvent in a ratioof 1:1. The floating microspheres were evaluated for flow properties, particle size,incorporation efficiency, as well as in-vitro floatability and drug release. The shape andsurface morphology of the microspheres were characterized by optical and scanningelectron microscopy. 20/32
  21. 21.  Publication number: EP2329810 A1 Publication date: Jun 8, 2011 Filing date: Nov 4, 2008 Priority date: Aug 18, 2008 Inventors: Qingwei Jiang, Quanzhi Liu, Wenbin Yang, Junli Zheng Applicant: Team Academy Of Pharmaceutical Science ABSTRACT: A gastroretentive drug delivery system is provided. Said system comprises a hollow vesicle and a drug-containing layer which surrounds the hollow vesicle. Said hollow vesicle preferably has a single chamber structure. The size in maximal diameter direction of said hollow vesicle is preferably 0.5-3.5 cm. The gastroretentive drug delivery system preferably contains an isolating layer and/or waterproofing layer between the hollow vesicle and the layer containing drug. 21/32
  22. 22.  Application Number: 10/514674 Publication Date: 05/11/2006 Filing Date: 05/21/2002 Inventors: Kumar, Manoj (Haryana, IN) Talwar, Naresh (New Delhi, IN) Raghuvanshi,Rajeev Singh (New Delhi, IN) Rampal, Ashok Kumar (Punjab, IN) Abstract: The present invention relates to an oral drug delivery system with biphasic release characteristics comprising a porous matrix comprising at least one drug substance, sugar(s), a release retarding polymer, gas generating components and optionally, pharma-ceuti-cally acceptable auxiliary components wherein the pharmaceutical composition further comprises a coating of said drug substance. The pharmaceutical composi-tion, either in the form of pellets (multiparticulate or single unit dosage form), beads, granules, capsules or tablets, is retained in the stomach while selectively delivering the drug(s) at gastrointestinal levels and upper parts of the small intestine over an extended period of time. The release of the drug from the said pharmaceutical composition is characterized by a biphasic release profile of the drug substance, which exhibits both immediate and controlled release characteristics. 22/32
  23. 23.  Application Number: PCT/GB1998/001513 Publication Date: 11/26/1998 Filing Date: 05/22/1998 Inventors: Illum Lisbeth, Ping He Abstract: There is provided a drug delivery composition for the controlled release of an active agent in the stomach environment over a prolonged period of time which comprises a microsphere comprising an active ingredient in the inner core of the microsphere and (i) a rate controlling layer of a water insoluble polymer and (ii) an outer layer of a bioadhesive agent in the form of a cationic polymer. 23/32
  24. 24.  Publication number: EP2276473 A1 Publication date: Jan 26, 2011 Filing date: Apr 17, 2009 Inventors: Giora Carni, David Kirmayer, Elena Kluev, Eytan Moor, Nadav Navon Applicant: Intec Pharma Ltd. ABSTRACT A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer. 24/32
  25. 25.  Publication number:EP1513508 A1 Publication date:Mar 16, 2005 Filing date:Jun 18, 2003 Inventors: Mohammad Hassan Applicant: Euro-Celtique S.A. ABSTRACT According to the present invention there is provided a pharmaceutical product for retention in the stomach. The product is produced by extrusion. The use of extrusion enables the product to take many useful forms. The product may comprise a sheet of hydratable polymer, the hydrated sheet being of a size which will not pass out of the stomach, for example a shaped sheet or a roll. The product may also comprise a sealed hollow tubular extrudate, for example a tube sealed at both ends. The product may comprise a filled capsule. 25/32
  26. 26.  Publication number: EP2378883 A2 Publication date: Oct 26, 2011 Filing date: Oct 19, 2009 Inventors: Giora Carni, David Kirmayer, Elena Kluev, Suher Masri, Eytan Moor, Nadav Navon Applicant: Intec Pharma Ltd. ABSTRACT: A biodegradable, multi-layered controlled release gastroretentive dosage form which is optionally divided into a first dosage of zaleplon for controlled release and a second dosage of zaleplon for immediate release in the stomach and gastrointestinal tract of a patient, folded into a capsule which disintegrates upon contact with gastric juice and the gastroretentive dosage form unfolds rapidly upon contact with gastric juice. The biodegradable, multi- layered gastroretentive dosage forms of the invention provide efficient sleep induction with good sleep maintenance and minimal next day residual effects. 26/32
  27. 27.  Application Number: 13/608994 Publication Date: 01/03/2013 Filing Date: 09/10/2012 Inventors: Muthusamy, Ramesh (Pune, IN) Kulkarni, Mohan Gopalkrishna (Pune, IN) Abstract: A gastroretentive, extended release composition which floats and swells at acidic pH prevalent in the stomach. The composition includes a pH dependent graft copolymer, a gellable polymer, a therapeutic agent, a gas generating system and pharmaceutically acceptable ingredients. The disclosed composition is useful to deliver the therapeutic agent within the stomach for an extended period of time. 27/32
  28. 28.  Filing Date: Oct 19, 2010 Publication Date: Apr 28, 2011 Application Number: IB2010/002867 Applicants/Inventors: NAVON, Nadav, 7 Sochovolsky St. 76656 Rehovot (IL) INTEC PHARMA LTD., 12 Hartom Street P.O. Box 45219 91450 Jerusalem (IL) Abstract: Disclosed is a multi-layered gastroretentive dosage form for the controlled release of a poorly soluble drug or diagnostic in the stomach and gastrointestinal tract of a patient, folded into a capsule which disintegrates rapidly and the said multi-layered dosage form unfolds rapidly upon contact with the gastric juice. The mechanisms of the gastric retention are not dependent on and do not influence the materials and methods used in controlling the release of the said poorly soluble drug. 28/32
  29. 29. Sr Title Type of Patent No. DateNo formulation1 Gastric retentive oral dosage form Swelling sysyem 10/769574 Dec 7, 2011 with restricted drug release in the lower gastrointestinal tract2 Extended release gastro-retentive Unfolding Sysyem EP2061438 A1 May 27, 2009 oral drug delivery system for valsartan3 Gastroretentive Composition On Gastroretentive Granules US20120269866 Oct 25, 2012 The Basis Of A Water-Soluble A1 Reaction Product From A Vinyl Group-Containing Precursor4 Novel Gas Releasing,Swelling Tablets 13121546 Nov 3, 2011 Gastroretentive Delivery System 29/32
  30. 30. Brand Name Formulation Active Ingredients MADOPAR® HBS (Roche) Capsule L-Dopa Liquid Gaviscon® (GSK) Floating Alginate Raft Antacid Almagate Flot-Coat® aluminium - magnesium antacidBeclofan GRS (Sun Pharma) - - Cifran OD (Ranbaxy) Tablet Ciprofloxacin Glumetza® Tablet (Acuform®) Metformin HCl Proquin® XR (Depomed) Ciprofloxacin HCl Coreg CR (GSK) Micropump® Carvdilol Phosphate 30/32
  31. 31. 1. , Accessed on 10-03-20132. Doshi S.M., Tank H.M., Gastro Retention – An Innovation over Conventional poorly Soluble Drugs : A review, International Journal of Pharmaceutical and chemcal Sciences, 2012;1(2):859-866.3. S. P. Vyas, Roop K. Khar, CONTROLLED DRUG DELIVERY – Concepts & Advances, Vallabh Prakashan, page no. 196-217.4. N. K. Jain, Progress in Controlled & Novel Drug Delivery Systems, 1st edition 2004, CBS Publishers, page no.76-975., Accessed on 10-03-20136. G. Chawla, P. Gupta, V. Koradia, A. K. Bansal, Pharmaceutical Technology July 2003, 50-687. Vyas, S.P.; Khar, R.Ks. Gastroretentive systems. In: Controlled drug Delivery. Vallabh Prakashan, Delhi, India. 2006.8., Accessed on 10-03-20139. International Journal of PharmTech Research10. Asian Journal of Biomedical and Pharmaceutical Sciences, 2 (8), 2012, 01-08 31/32
  32. 32. GRDDS 32/32